Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon in chronic myeloid leukemia. A workshop report.
Griesshammer M, Hehlmann R, Hochhaus A, Talpaz M, Tura S, Stryckmans P, Allan NC, Tanzer J, Kolb HJ, Heimpel H. Griesshammer M, et al. Among authors: kolb hj. Ann Hematol. 1993 Aug;67(2):101-6. doi: 10.1007/BF01788134. Ann Hematol. 1993. PMID: 8347729 Review.
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.
Hehlmann R, Heimpel H, Hossfeld DK, Hasford J, Kolb HJ, Löffler H, Pralle H, Queisser W, Hochhaus A, Tichelli A, Fett W, Schmitz N, Reiter A, Griesshammer M, Pfeifer W, Bümler M, Kamp T, Tobler A, Eimermacher H, Kuse R, Berger U, Ansari H. Hehlmann R, et al. Among authors: kolb hj. Bone Marrow Transplant. 1996 May;17 Suppl 3:S21-4. Bone Marrow Transplant. 1996. PMID: 8769695 Clinical Trial.
Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group.
Hehlmann R, Ansari H, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Reiter A, Hochhaus A. Hehlmann R, et al. Among authors: kolb hj. Br J Haematol. 1997 Apr;97(1):76-85. doi: 10.1046/j.1365-2141.1997.102652.x. Br J Haematol. 1997. PMID: 9136944 Free article. Clinical Trial.
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure.
Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H, Siegert W, Finke J, Ehninger G, Holler E, Berger U, Pfirrmann M, Muth A, Zander A, Fauser AA, Heyll A, Nerl C, Hossfeld DK, Löffler H, Pralle H, Queisser W, Tobler A. Hehlmann R, et al. Among authors: kolb hj. Blood. 1999 Dec 1;94(11):3668-77. Blood. 1999. PMID: 10572078 Free article. Clinical Trial.
Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group.
Hehlmann R, Kister P, Willer A, Simon M, Schenk M, Seifarth W, Papakonstantinou G, Saussele S, Kolb HJ, Ansari H, et al. Hehlmann R, et al. Among authors: kolb hj. Leukemia. 1994 Apr;8 Suppl 1:S127-32. Leukemia. 1994. PMID: 8152279 Review.
485 results